Review anchor
Prostaglandin E2 receptor EP4 subtype
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
Evidence Snapshot
Prostaglandin E2 receptor EP4 subtype
CHEMBL1836
SINGLE PROTEIN
Homo sapiens
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Prostaglandin E2 receptor EP4 subtype as ChEMBL target CHEMBL1836, mapped to UniProt P35408. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL1836
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P35408
Prostaglandin E2 receptor EP4 subtype
UniProt accession via ChEMBL component mapping
As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-13
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why Prostaglandin E2 receptor EP4 subtype matters
Prostaglandin E2 receptor EP4 subtype is reviewed as Prostaglandin E2 receptor EP4 subtype (UniProt P35408); Prostaglandin E2 receptor EP4 subtype shows clinical signal disease relevance led by rheumatoid arthritis. 5 more disease programs remain visible in the same review block.; 1 linked drug keep this evidence frame grounded.; the current evidence base includes 4 approved drugs, 1618 compounds, and 282 assays, with lead potency reaching pChEMBL 11.0.
Protein context
Prostaglandin E2 receptor EP4 subtype
Prostaglandin E2 receptor EP4 subtype Sequence length is 488 aa.
Review this target as Prostaglandin E2 receptor EP4 subtype, mapped to UniProt P35408. Sequence length is 488 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt P35408
Protein
Disease context
rheumatoid arthritis
Prostaglandin E2 receptor EP4 subtype shows clinical signal disease relevance led by rheumatoid arthritis. 5 more disease programs remain visible in the same review block. 1 linked drug keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include VORBIPIPRANT.
Start review with rheumatoid arthritis because it currently carries clinical signal support. Linked drugs include VORBIPIPRANT. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target record
Clinical signal
1 linked drug
Activity base
Portfolio and assay base
ChEMBL currently tracks 4 approved drugs, 1618 compounds, and 282 assays for this target. The dominant activity type is IC50. CHEMBL292964 is the current potency anchor at pChEMBL 11.0.
Use CHEMBL292964 as the tractability anchor when discussing potency (pChEMBL 11.0).
Activity source · ChEMBL 36 via Core Engine
4 approved
pChEMBL 11.0
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why Prostaglandin E2 receptor EP4 subtype matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt P35408, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need to see why rheumatoid arthritis is currently treated as clinical signal support.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
1618
Total Compounds
282
Total Assays
4
Approved Drugs
IC50: 925.0, KI: 819.0, EC50: 447.0, KD: 8.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL292964
|
11.0 | EC50 | — |
|
|
No preferred name
CHEMBL3959605
|
11.0 | EC50 | — |
|
|
No preferred name
CHEMBL3975743
|
11.0 | EC50 | — |
|
|
No preferred name
CHEMBL5945805
|
10.8 | EC50 | — |
|
|
No preferred name
CHEMBL3937596
|
10.8 | EC50 | — |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
DINOPROSTONE
CHEMBL548
|
1977 |
Source Header